Satri-cel: New Treatment Option for Stomach & GEJ Cancer
Table of Contents
Plan Your Treatment
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Gastric cancer remains one of the leading causes of cancer-related deaths worldwide. Many patients with advanced or metastatic gastric cancer eventually experience disease progression despite chemotherapy, targeted therapy, or immunotherapy. In recent years, CAR-T cell therapy has emerged as a promising new approach in cancer treatment, and Satri-cel has become one of the most closely watched therapies for gastric cancer.
Satri-cel is a Claudin18.2-targeted CAR-T cell therapy developed for patients with advanced gastric cancer and gastroesophageal junction (GEJ) adenocarcinoma. Early clinical studies have shown encouraging anti-tumor activity in heavily pretreated patients, offering new hope for individuals with limited treatment options.
What Is Satri-cel?
Satri-cel is an autologous CAR-T cell therapy targeting Claudin18.2 (CLDN18.2), a protein highly expressed in many gastric and gastroesophageal junction cancers. CAR-T therapy works by collecting a patient’s own T cells, genetically modifying them in the laboratory to recognize cancer cells, and reinfusing them back into the patient to attack the tumor.
Unlike traditional chemotherapy, which affects both healthy and cancerous cells, Satri-cel is designed to specifically recognize CLDN18.2-positive tumor cells. This targeted approach may improve anti-tumor activity while reducing damage to normal tissues.
Why Claudin18.2 Matters in Gastric Cancer
Claudin18.2 is considered one of the most important emerging targets in gastric cancer treatment. The protein is normally found in gastric mucosal cells but becomes highly exposed in malignant gastric tumors, making it an attractive target for immunotherapy.
A significant proportion of gastric and gastroesophageal junction adenocarcinomas express CLDN18.2. Patients whose tumors test positive for this biomarker may be eligible for CLDN18.2-targeted therapies such as Satri-cel.
Biomarker testing through immunohistochemistry (IHC) is usually required before treatment to determine whether the tumor expresses sufficient levels of Claudin18.2.
Potential Benefits of Satri-cel
Promising Clinical Activity
Clinical studies have shown encouraging response rates in patients with advanced gastric cancer who previously received multiple lines of treatment. Some patients experienced significant tumor shrinkage, prolonged disease control, and durable responses.
Personalized Cellular Therapy
Satri-cel uses the patient’s own immune cells, creating a personalized treatment approach tailored to the individual’s cancer biology.
New Option After Standard Therapy Failure
Many patients with metastatic gastric cancer eventually exhaust standard treatment options. Satri-cel may provide another therapeutic possibility for eligible patients with relapsed or refractory disease.
Potential Activity in Difficult-to-Treat Disease
CAR-T cell therapy may help overcome some limitations associated with conventional therapies, particularly in patients with aggressive or treatment-resistant tumors.
Who May Be Eligible for Satri-cel?
Patients may be considered for Satri-cel therapy if they:
- Have advanced or metastatic gastric cancer
- Have gastroesophageal junction adenocarcinoma
- Test positive for Claudin18.2 expression
- Previously received standard treatments
- Have adequate organ function and overall condition for cellular therapy
Eligibility requirements may vary depending on the treatment center, clinical protocol, and individual patient condition.
Treatment Process
The Satri-cel treatment process generally includes several steps:
1. Medical Evaluation
Doctors review the patient’s medical history, pathology reports, imaging studies, and biomarker results to determine eligibility.
2. T-Cell Collection
The patient undergoes leukapheresis, a procedure used to collect immune cells from the blood.
3. CAR-T Cell Manufacturing
The collected T cells are genetically engineered and expanded in a specialized laboratory to create Satri-cel CAR-T cells.
4. Lymphodepletion Chemotherapy
Before CAR-T infusion, patients usually receive short-course chemotherapy to prepare the body for the engineered cells.
5. CAR-T Cell Infusion
The modified CAR-T cells are infused back into the patient to target and attack CLDN18.2-positive cancer cells.
6. Monitoring and Follow-Up
Patients are closely monitored for treatment response and potential side effects following infusion.
Get Satri-cel in China
China has become one of the global leaders in CAR-T cell therapy research and clinical development, particularly in solid tumors such as gastric cancer. Several advanced medical centers and oncology hospitals in China are actively involved in cellular immunotherapy programs and innovative cancer treatment strategies.
International patients seeking advanced gastric cancer treatment may explore access to Satri-cel-related therapies and evaluation through specialized medical centers in China.
Availability
CAR-T cell therapy is the latest breakthrough in the treatment of solid tumors like stomach cancer. It is only available in China.
Faster access to treatment
In many countries, CAR-T therapy involves long waiting lists or complex approval processes. In China, patients can often begin evaluation and treatment much sooner.
60% less in cost
Compared to the U.S. and parts of Europe, the overall cost of CAR-T cell therapy for multiple myeloma in China is significantly lower, while still maintaining high medical standards.
Extensive clinical experience
CAR-T centers in China have treated a large number of multiple myeloma patients with CAR-T therapy, contributing to strong clinical expertise and refined treatment protocols.
Personalized treatment planning
Patients receive individualized assessments and treatment strategies based on disease status, prior therapies, and overall health.
Integrated supportive care
From pre-treatment evaluation to post-infusion monitoring, patients benefit from structured care pathways designed to manage side effects and improve outcomes.
Targeted Approach
CAR T-cell therapy specifically targets antigens on myeloma cells, such as BCMA (B-cell maturation antigen). This precision helps to effectively eliminate cancer cells while sparing healthy cells, reducing collateral damage.
Personalized Treatment
CAR T-cell therapy uses the patient’s own T-cells, which are genetically modified to recognize and attack cancer cells, offering a tailored approach to each individual’s disease.
High Efficacy
CAR T-cell therapy has shown significant effectiveness, leading to deep and durable remissions in many patients, particularly those who have relapsed or become refractory to other treatments.
Potential for Long-term Control
Many patients experience deep and lasting remissions after CAR T-cell therapy, even those who have relapsed or become refractory to conventional treatments. This potential for long-term disease control is a significant benefit.
Improved Quality of Life
Successful treatment can lead to a better quality of life post-therapy, as patients may experience fewer side effects than with conventional treatments.
Short Treatment Duration
Unlike some conventional therapies that may take months, CAR T-cell treatment can often be administered within a shorter time frame after T-cell collection and modification.
Expertise in treating solid tumors
CAR T Cells China associated cancer care experts specialize in the diagnosis and treatment of cancers, including stomach cancer, across all stages — from early to advanced, as well as rare and complex cases. Our oncology team integrates standard treatments with the latest innovations, including CAR-T cell therapy, a cutting-edge form of immunotherapy that reprograms the patient’s own immune cells to fight cancer. We also offer precision medicine approaches and targeted therapies, ensuring each patient receives care tailored to their specific cancer profile. Qualified patients may also gain access to clinical trials and investigational CAR-T therapies, giving them the opportunity to benefit from the most advanced treatment options available today.
We help you out at every step of your CAR-T journey
Cancer is a complex disease that involves multiple appointments, specialized treatments, medications, and ongoing follow-up care — all of which can feel overwhelming, especially for international patients. At CAR T Cell China, we understand these challenges and are committed to supporting you every step of the way. That’s why we’ve developed a dedicated international patient care model, where a personal care coordinator or team is assigned to help manage the entire treatment journey — from visa support and travel logistics to hospital navigation and medical appointments.
Your care manager at CAR T Cell China is a highly trained nurse or patient liaison with deep expertise in cancer care and CAR-T therapy. They serve as your primary point of contact, coordinating everything from consultations with top specialists to treatment scheduling, medication support, and ongoing communication with your medical team.
As a trusted bridge between you and your care providers, your care manager ensures that no detail is overlooked — allowing you to focus fully on your recovery, while we handle the rest.
Every detail matters
Finding the right cancer treatment center and care team is one of the most important decisions you’ll make — especially when seeking care abroad. At CAR T Cell China, we understand the weight of that decision and the stress it can bring. That’s why we are committed to making your experience as convenient, affordable, and worry-free as possible. From personalized care coordination to access to cutting-edge CAR-T therapy, we work every day to ensure that international patients receive not only world-class treatment, but also the dedicated support they need throughout their journey. Here are just a few of the key advantages of choosing CAR T Cell China as your care destination.
Working with you for long-term management
Our commitment to your care doesn’t end after your CAR-T infusion — it continues throughout your entire recovery journey. From the moment you begin treatment, our team works closely with you to support your overall health and well-being. Once your primary CAR-T therapy is complete, you’ll be introduced to our survivorship care team, who will help monitor for any signs of relapse, manage long-term side effects, and support your return to daily life. They also coordinate ongoing communication with your primary care physician back home and offer personalized guidance on maintaining a healthy lifestyle after cancer. Whether you’re still in China or back in your home country, your care team remains just a phone call or message away, ready to support you every step of the way.
Get a second opinion
Being diagnosed with a serious illness like cancer can turn your world upside down — and the decisions you make next are crucial to achieving the best possible outcome. At CAR T Cell China, we believe that you deserve to fully understand all of your options so you can confidently participate in decisions about your care.
Even if you’ve already started treatment elsewhere, you can still seek a second opinion from our leading CAR-T specialists.
Our expert team will carefully review your diagnosis, assess your treatment history, and provide clear insights into the most advanced CAR-T therapies and clinical options available in China. We take time to listen to your concerns, answer your questions, and help you make informed choices. Our experience comes from treating blood cancers at every stage, every day. Contact us today to schedule your second opinion consultation — and take the next step with confidence.
Frequently Asked Questions
What is Satri-cel?
Satri-cel (CT041) is a CAR-T cell therapy that targets Claudin 18.2 (CLDN18.2), a protein commonly found on gastric (stomach) cancer and gastroesophageal junction (GEJ) cancer cells.
Who may be eligible for Satri-cel?
Patients with advanced or metastatic CLDN18.2-positive gastric or GEJ cancer who have progressed after standard treatments may be candidates, subject to physician evaluation.
How do I know if my tumor is CLDN18.2-positive?
A pathology test called immunohistochemistry (IHC) can determine whether your tumor expresses CLDN18.2 and if you may qualify for treatment.
How is Satri-cel administered?
The process includes T-cell collection, CAR-T cell manufacturing, lymphodepletion chemotherapy, and a single CAR-T cell infusion followed by close monitoring.
What are the potential benefits of Satri-cel?
Clinical studies have shown encouraging tumor response rates and durable disease control in some patients with heavily pretreated gastric cancer.
Can international patients receive Satri-cel in China?
Yes. Eligible international patients may access Satri-cel treatment in China following medical review and acceptance by the treating center.
How can I find out if I am a candidate?
Patient Videos
Hear directly from patient as they share their journey of undergoing CAR-T cell therapy for stomach cancer in China. From the decision to seek advanced treatment abroad to the experience of care and recovery, this video offers a personal perspective on what patients and families can expect throughout the process.
Latest articles
